Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide

Medicin og biovidenskab

• rGLP-1 protein 100%
• Pharmacokinetics 41%
• Glucagon-Like Peptide-1 Receptor 19%
• Placebos 13%
• Type 2 Diabetes Mellitus 7%
• Liraglutide 7%
• Safety 5%
• Glycated Hemoglobin A 5%
• Pancreatitis 4%
• Half-Life 4%
• Nausea 4%
• Vomiting 4%
• Risk Assessment 4%
• Diarrhea 4%
• Weight Loss 4%
• Fasting 4%
• Central Nervous System 3%
• Clinical Trials 3%
• Glucose 3%
• Kidney 2%
• Pharmaceutical Preparations 2%
• Therapeutics 1%